재고 위치
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* 재고 가용성에 따라 다름
Documentation
포함 사항: HPLC, MASS/LC-MS, 1H NMR, FT-IR, 함량, 구조 규명 보고서(SER), 그리고 제품에 따라 추가 분석 데이터가 제공됩니다.
Empagliflozin monoacetyl impurity
● 재고 있음
| 카탈로그 번호: | VL2480009 |
|---|---|
| CAS 번호: | N/A |
| 분자식: | C25H29ClO8 |
| 분자량: | 492.95 g/mol |
에 대한 추가 정보 Empagliflozin monoacetyl impurity
모약물
EmpagliflozinIUPAC명
((2R, 3S, 4R, 5R, 6S)-6-(4-chloro-3-(4-(((R)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-3, 4, 5-trihydroxytetrahydro-2H-pyran-2-yl)methyl acetate약전 동의어
N/AOther Synonyms
N/ASMILES
CC(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C2=CC=C(Cl)C(CC3=CC=C(O[C@H]4COCC4)C=C3)=C2)O1)=OInChI
InChI=1S/C25H29ClO8/c1-14(27)32-13-21-22(28)23(29)24(30)25(34-21)16-4-7-20(26)17(11-16)10-15-2-5-18(6-3-15)33-19-8-9-31-12-19/h2-7,11,19,21-25,28-30H,8-10,12-13H2,1H3/t19-,21-,22-,23+,24-,25+/m1/s1설명
The compound Empagliflozin monoacetyl impurity is a well-documented reference standard that adheres to strict regulatory requirements set by USP EMA JP and BP. It’s highly suited for use in various applications like analytical method development method validation (AMV) and quality control (QC) especially when manufacturing Empagliflozin. Whether you’re preparing for ANDA or NDA submissions, this product provides the accuracy you need. Plus, it comes with a comprehensive Structure Elucidation Report (SER), which ensures its reliability for precise analytical work.” Empagliflozin monoacetyl impurity or ((2R,3S,4R,5R,6S)-6-(4-chloro-3-(4-(((R)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl acetate. Empagliflozin is a potent, highly selective, sodium-glucose cotransporter-2(SGLT-2) inhibitor. It is well-tolerated antihyperglycemic for the treatment of type-2 diabetes. It reduces renal reabsorption of glucose.
References
“Wanner, Christoph, et al. “Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.†New England Journal of Medicine, vol. 375, no. 4, July 2016, pp. 323–34, https://doi.org/10.1056/nejmoa1515920. ?Frampton, James E. “Empagliflozin: A Review in Type 2 Diabetes.†Drugs, vol. 78, no. 10, June 2018, pp. 1037–48, https://doi.org/10.1007/s40265-018-0937-z. ?”견적 요청
"*" indicates required fields
와 관련된 기타 제품 Empagliflozin impurities
Empagliflozin
